Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Argus Health
Farmers Insurance
Daiichi Sankyo
Accenture
Healthtrust
Colorcon
Julphar
Johnson and Johnson

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IRON SUCROSE

« Back to Dashboard

Clinical Trials for Iron Sucrose

Trial ID Title Status Sponsor Phase Summary
NCT00111956 Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00125996 Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure Unknown status 4th Military Hospital, Poland Phase 1/Phase 2 This is a two-center, randomised, single-blind (physician), prospective, controlled study to assess the acute (8 weeks) and chronic (16 weeks) effects of intravenous (IV) iron sucrose supplementation in anaemic and non-anaemic iron deficient patients with chronic heart failure (CHF). The hypotheses are: - Treatment of anaemic and non-anaemic iron-deficient CHF patients with IV iron sucrose improves exercise capacity as measured by peak VO2. - IV iron sucrose is safe and well tolerated in subjects with moderate to severe CHF.
NCT00125996 Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure Unknown status Wexham Park Hospital Phase 1/Phase 2 This is a two-center, randomised, single-blind (physician), prospective, controlled study to assess the acute (8 weeks) and chronic (16 weeks) effects of intravenous (IV) iron sucrose supplementation in anaemic and non-anaemic iron deficient patients with chronic heart failure (CHF). The hypotheses are: - Treatment of anaemic and non-anaemic iron-deficient CHF patients with IV iron sucrose improves exercise capacity as measured by peak VO2. - IV iron sucrose is safe and well tolerated in subjects with moderate to severe CHF.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Iron Sucrose

Condition Name

Condition Name for Iron Sucrose
Intervention Trials
Anemia 20
Pain 14
Iron Deficiency Anemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Iron Sucrose
Intervention Trials
Anemia, Iron-Deficiency 32
Anemia 28
Kidney Diseases 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Iron Sucrose

Trials by Country

Trials by Country for Iron Sucrose
Location Trials
United States 61
Canada 15
United Kingdom 7
Austria 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Iron Sucrose
Location Trials
Pennsylvania 8
Massachusetts 6
Maryland 5
Colorado 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Iron Sucrose

Clinical Trial Phase

Clinical Trial Phase for Iron Sucrose
Clinical Trial Phase Trials
Phase 4 28
Phase 3 29
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Iron Sucrose
Clinical Trial Phase Trials
Completed 61
Recruiting 23
Unknown status 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Iron Sucrose

Sponsor Name

Sponsor Name for Iron Sucrose
Sponsor Trials
Luitpold Pharmaceuticals 12
AMAG Pharmaceuticals, Inc. 4
Vifor Inc. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Iron Sucrose
Sponsor Trials
Other 104
Industry 49
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Federal Trade Commission
Moodys
Harvard Business School
US Department of Justice
Covington
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.